Results 161 to 170 of about 21,229 (228)

Mechanistic basis for inhibition of the extended-spectrum β-lactamase GES-1 by enmetazobactam and tazobactam. [PDF]

FEBS Lett
Beer M, Hinchliffe P, Hanževački M, Bethel CR, Tooke CL, Van der Kamp MW, Papp-Wallace KM, Bonomo RA, Shapiro S, Mulholland AJ, Spencer J.   +10 more
europepmc   +1 more source

Epidemiology, drug resistance, and molecular features of Klebsiella pneumoniae in Southwest Shandong, China. [PDF]

Sci Rep
Han L, Yang C, Shi J, Du L, Sun J, Li W, Lu S.   +6 more
europepmc   +1 more source

Evaluation of Colistin Susceptibility of <i>Klebsiella pneumoniae</i> Strains Exposed to Rotating Magnetic Field. [PDF]

Int J Mol Sci
Pruss A, Kobylińska D, Fijałkowski K, Masiuk H, Kwiatkowski P.   +4 more
europepmc   +1 more source

Extended-spectrum beta-lactamases: definition, history, an update on their genetic environment and detection methods. [PDF]

J Med Microbiol
Yassara S, Zeouk I, Jaouhar S, Sbiti M, Bekhti K.   +4 more
europepmc   +1 more source

Beta-Lactamases and ESBL

Virology & Immunology Journal, 2019
openaire   +1 more source

Pharmacokinetics/Pharmacodynamics-Based Repositioning of Cefmetazole and Flomoxef in Extended-Spectrum β-Lactamase-Producing Enterobacterales Treatment: An Injectable Carbapenem-Sparing and Outpatient Strategy. [PDF]

Antibiotics (Basel)
Kato T, Yagi Y, Maruyama T, Hamada Y.
europepmc   +1 more source

Genomic characterization of <i>Klebsiella pneumoniae</i> clinical isolates from cancer patients: resistance profiles, virulence factors, and sequence typing. [PDF]

Front Microbiol
Liu H, Liu W, Zhou X, Wang X, Huang G.
europepmc   +1 more source

Analysis of Bacterial Coinfections in Patients with Mild, Moderate, and Severe COVID-19. [PDF]

Pol J Microbiol
Liu Q, Bei Gao J, Zheng Hu H, Zheng Jiao F, Gao X, Yan Wu B.   +5 more
europepmc   +1 more source

Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review). [PDF]

Exp Ther Med
Abouelkheir M, Taha AE, Taher IA, Saad Eldien HM, Bakhaat GA.   +4 more
europepmc   +1 more source

Efficacy and <i>in vitro</i> activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). [PDF]

Antimicrob Agents Chemother
Scangarella-Oman NE, Butler DL, Breton J, Brown D, Kasapidis C, Sheets AJ.   +5 more
europepmc   +1 more source